Trial reportRespiratory research2013
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.
Trial report in Respiratory research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00563381 (Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of Early Pulmonary Rehabilitation on Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2023Pooled it
- Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression.Respiratory research · 2019Pooled it
- A Chronic Obstructive Pulmonary Disease Self-Management Intervention for Improving Patient-Reported Outcomes in Primary Care in Greece.Medicina (Kaunas, Lithuania) · 2024Trial
- Follow-up interviews from The Salford Lung Study (COPD) and analyses per treatment and exacerbations.NPJ primary care respiratory medicine · 2019Trial
- Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.International journal of chronic obstructive pulmonary disease · 2017Trial
- Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).Advances in therapy · 2015Trial
- Trial
- Treatable traits identified in Chinese patients hospitalized with AECOPD: A Multicenter Cohort Study.International journal of medical sciences · 2025Article
- Respiratory virus infections and adenovirus characteristics during acute exacerbation of chronic obstructive pulmonary disease.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- Chronic obstructive pulmonary disease (COPD) and COPD-like phenotypes.Frontiers in medicine · 2024Review
- Risk and distribution of chronic obstructive pulmonary disease-related hospitalizations among primary care patients.Canadian family physician Medecin de famille canadien · 2023Article
- Association of rural living with COPD-related hospitalizations and deaths in US veterans.Scientific reports · 2023Article
- Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2022Article
- Increased mortality associated with frequent exacerbations in COPD patients with mild-to-moderate lung function impairment, and smokers with normal spirometry.Respiratory medicine: X · 2021Article
- Towards precision in defining COPD exacerbations.Breathe (Sheffield, England) · 2021Review
- Impact of gender on chronic obstructive pulmonary disease outcomes: a propensity score-matched analysis of a prospective cohort study.The Korean journal of internal medicine · 2020Article
- Total Antioxidant Status in Stable Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2020Article
- Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.International journal of chronic obstructive pulmonary disease · 2020Article
- Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD.International journal of chronic obstructive pulmonary disease · 2020Article
- Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.International journal of chronic obstructive pulmonary disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData examining the characteristics of patients with frequent exacerbations of chronic obstructive pulmonary disease (COPD) and associated hospitalisations and mortality are scarce.
methodsPost-hoc analysis of the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial, targeting exacerbations as the primary endpoint. Patients were classified as non-, infrequent, and frequent exacerbators (0, 1, or ≥ 2 exacerbations during study treatment), irrespective of study treatment. A multivariate Cox regression model assessed the effect of covariates on time to first exacerbation.
resultsIn total, 7376 patients were included in the analysis: 63.5% non-exacerbators, 22.9% infrequent, 13.6% frequent exacerbators. Factors significantly associated with exacerbation risk were age, sex, body mass index, COPD duration and severity, smoking history, baseline inhaled corticosteroid use, and preceding antibiotic or systemic corticosteroid courses. Frequent exacerbators had greater severity and duration of COPD, received more pulmonary medication, and ≥ 2 systemic corticosteroid or antibiotic courses in the preceding year, and were more likely to be female and ex-smokers. The small proportion of frequent exacerbators (13.6%) accounted for 56.6% of exacerbation-related hospitalisations, which, overall, were associated with a three-fold increase in mortality.
conclusionThe frequent exacerbator phenotype was closely associated with exacerbation-related hospitalisations, and exacerbation-related hospitalisations were associated with poorer survival.
trial registrationNCT00563381; Study identifier: BI 205.389.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.